161 related articles for article (PubMed ID: 15944795)
1. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.
Yatsenko T; Rios R; Nogueira T; Takahashi S; Tabe Y; Naito T; Takahashi K; Hattori K; Heissig B
Front Immunol; 2023; 14():1299792. PubMed ID: 38313435
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M
J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867
[TBL] [Abstract][Full Text] [Related]
5. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
[TBL] [Abstract][Full Text] [Related]
6. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N; Mihalcioiu C; Rabbani SA
Front Oncol; 2018; 8():24. PubMed ID: 29484286
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.
Beaulieu LM; Whitley BR; Wiesner TF; Rehault SM; Palmieri D; Elkahloun AG; Church FC
Bioessays; 2007 Oct; 29(10):1029-38. PubMed ID: 17876797
[TBL] [Abstract][Full Text] [Related]
8. uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
Uhl B; A Mittmann L; Dominik J; Hennel R; Smiljanov B; Haring F; B Schaubächer J; Braun C; Padovan L; Pick R; Canis M; Schulz C; Mack M; Gutjahr E; Sinn P; Heil J; Steiger K; Kanse SM; Weichert W; Sperandio M; Lauber K; Krombach F; Reichel CA
EMBO Mol Med; 2021 Jun; 13(6):e13110. PubMed ID: 33998175
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model.
Furuya H; Hayashi K; Shimizu Y; Kim N; Tsukikawa Y; Chen R; Sun Y; Chan OTM; Pagano I; Peres R; Hokutan K; Igari F; Chan KS; Rosser CJ
J Transl Med; 2020 Feb; 18(1):57. PubMed ID: 32024545
[TBL] [Abstract][Full Text] [Related]
10. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection.
Ly D; Donahue D; Walker MJ; Ploplis VA; McArthur JD; Ranson M; Castellino FJ; Sanderson-Smith ML
Microbes Infect; 2019; 21(8-9):412-417. PubMed ID: 31009808
[TBL] [Abstract][Full Text] [Related]
12. The Roles of Fibrinolytic Factors in Bone Destruction Caused by Inflammation.
Kanno Y
Cells; 2024 Mar; 13(6):. PubMed ID: 38534360
[TBL] [Abstract][Full Text] [Related]
13. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
Hao W; Friedman A
PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
[TBL] [Abstract][Full Text] [Related]
14. Investigate the potential impact of Hemagglutinin from the H1N1 strain on severe pneumonia.
Zheng YB; Lu S; Chu TB; Pang GF; Yang LY; Zhang Q
Gene; 2024 May; ():148559. PubMed ID: 38740352
[TBL] [Abstract][Full Text] [Related]
15. Protein Microarrays for Quantitative Detection of PAI-1 in Serum.
Ma X; Zhang QY
Chin J Cancer Res; 2012 Sep; 24(3):220-5. PubMed ID: 23358703
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic Stability of Alteplase Solution for Injection: Effect of Various Methods of Thawing Frozen Solutions.
Cutshall BT; Gorman GS; Freeman MK; Kyle JA
Hosp Pharm; 2016 Mar; 51(3):246-251. PubMed ID: 38745574
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.
Fang L; Xu Q; Qian J; Zhou JY
Onco Targets Ther; 2021; 14():53-65. PubMed ID: 33442266
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Honma N; Inoue T; Tsuchiya N; Koizumi A; Yamamoto R; Nara T; Kanda S; Huang M; Numakura K; Saito M; Narita S; Satoh S; Habuchi T
Health Sci Rep; 2020 Dec; 3(4):e197. PubMed ID: 33088925
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Abbink K; Zusterzeel PLM; Geurts-Moespot A; van der Steen R; Span PN; Sweep FCGJ
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1725-1735. PubMed ID: 32394054
[TBL] [Abstract][Full Text] [Related]
20. An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.
Fowler CB; Man YG; Mason JT
J Cancer; 2014; 5(2):115-24. PubMed ID: 24494029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
